CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

Sep 17 2009

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D. The increased interest in the immunotherapy companies and growth of the sector followed the positive Phase III results of Dendreon (NASDAQ:DNDN), a CI Index component company, for its prostate cancer product and resulting 1,000% share price improvement during the Spring of 2009.

In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body’s own immune system is triggered to attack cancer cells. The different companies target different proteins for different cancers or cancer components. Patients report only flu-like symptoms as their now activated natural defenses attempt to eradicate or stabilize the targeted cancers. The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 Billion. The current combined market cap of the index component companies is $3.6 Billion. In addition to ImmunoCellular Therapeutics and Dendreon, the CI Index features Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (PINK SHEETS:BVTI), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (NWBO.OB), CEL – SCI Corp. (AMEX:CVM), Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express and Mentor Capital, Inc. (PINK SHEETS:MNTR) as proxy for its investee Quantum Immunologics, Inc.

http://www.imuc.com